Who is sponsoring NCT02483364?

NCT02483364 is sponsored by Salvat.

What drugs are being tested in NCT02483364?

Interventions in NCT02483364: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment).

What condition does NCT02483364 study?

NCT02483364 studies Pseudoarthrosis.

Is NCT02483364 still recruiting?

NCT02483364 is currently completed. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT02483364: Bonecure

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure)

Completed Phase 2 Last updated 17 March 2021

What this trial tests

Phase 2 trial testing HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment) in Pseudoarthrosis in 12 participants. Completed in 20 October 2020.

Timeline

10 November 2015

Primary endpoint
18 May 2020

20 October 2020

Quick facts

Lead sponsor	Salvat
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	10 November 2015
Primary completion	18 May 2020
Estimated completion	20 October 2020
Sites	1 location across Spain

Drugs / interventions tested

HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)

Conditions studied

Pseudoarthrosis — all drugs for Pseudoarthrosis →

Sponsor

Salvat — full company profile →

Who can join

Adults 18 to 65, any sex, with Pseudoarthrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose os this study is to evaluate the safety and effectiveness of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of atrophic nonunion in long bones.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Adult Stem Cells for Bone Regeneration and Repair.
Iaquinta MR, Mazzoni E, Bononi I, Rotondo JC, et al · · 2019 · cited 176× · PMID 31799249 · DOI 10.3389/fcell.2019.00268
Mesenchymal Stromal Cell-Based Bone Regeneration Therapies: From Cell Transplantation and Tissue Engineering to Therapeutic Secretomes and Extracellular Vesicles.
Marolt Presen D, Traweger A, Gimona M, Redl H. · · 2019 · cited 104× · PMID 31828066 · DOI 10.3389/fbioe.2019.00352
Recent advances of biomaterials in biotherapy.
Li L, He ZY, Wei XW, Wei YQ. · · 2016 · cited 37× · PMID 27047675 · DOI 10.1093/rb/rbw007
Frontiers in non-union research.
Gómez-Barrena E, Padilla-Eguiluz NG, Rosset P. · · 2020 · cited 18× · PMID 33204499 · DOI 10.1302/2058-5241.5.190062
Efficacy and safety of autologous or allogeneic mesenchymal stromal cells from adult adipose tissue expanded and combined with tricalcium phosphate biomaterial for the surgical treatment of atrophic nonunion of long bones: a phase II clinical trial.
Orozco Delclós L, Soler Rich R, Arriaza Loureda R, Moreno García A, et al · · 2024 · cited 10× · PMID 38789992 · DOI 10.1186/s12967-024-05280-x
Biomaterials Mimicking Mechanobiology: A Specific Design for a Specific Biological Application.
Donati L, Valicenti ML, Giannoni S, Morena F, et al · · 2024 · cited 5× · PMID 39408716 · DOI 10.3390/ijms251910386
An overview of stem cells and cell products involved in trauma injury.
Saeedi P, Nilchiani LS, Zand B, Hajimirghasemi M, et al · · 2025 · cited 1× · PMID 40143930 · DOI 10.1016/j.reth.2025.02.011

Verify or expand the search:

Other Salvat trials

Trials by the same sponsor.

NCT05724446 — Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatri · Phase 3 · recruiting
NCT04246801 — Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract · Phase 3 · completed
NCT03686397 — SVT-15652 Otic Solution for the Treatment of Otomycosis. · Phase 3 · completed
NCT04249076 — Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract · Phase 3 · completed
NCT03686384 — SVT-15652 Otic Solution for the Treatment of Otomycosis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02483364 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Salvat
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02483364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing